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     Abstract 
Apolipoprotein (APOE), vitamin B12, and folate were examined in relation to free recall 
among 167 community-based older adults (M=82.81 years). Cognitive support at encoding 
and retrieval was also taken into account. Participants were classified as APOE ε4 or non-ε4 
allele carriers, and as either low or normal vitamin B12 or folate status. A significant 
association was identified between low vitamin B12, and the ε4 genotype in respect to free 
recall, but only in circumstances of low cognitive support. This result was retained having 
removed incident dementia cases up to six years following testing. A similar, but 
nonsignificant, trend was evident in relation to folate. The research is discussed with reference 
to vulnerability models, and genetic influences on brain reserves. 
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Introduction 
Psychosocial models of life stress propose that the vulnerability of an individual faced with a 
stressful life event to adverse health consequences, is moderated by the combined influence 
of pre-existing personal dispositions and prevailing social conditions (e.g., Dohrenwend & 
Dohrenwend, 1981). Individuals of a particular disposition may be more vulnerable to 
negative outcomes if detrimental social conditions exist. A parallel exists between these 
vulnerability models and research investigating genetic associations with cognitive function 
in old age, and the extent to which non-genetic factors may influence such associations. It is 
possible that individuals of a particular genetic disposition are more vulnerable to cognitive 
deficits in later life given certain environmental conditions. Here, we test this vulnerability 
hypothesis in non-demented adults aged 75 years and older. Specifically, we investigated 
episodic memory performance in relation to apolipoprotein E (APOE), and two nutritional 
variables, vitamin B12 and folate. We evaluated how far APOE genotype and low B vitamin 
levels rendered individuals vulnerable to episodic memory deficits in old age. Also, task 
demands were taken into account by varying the level of cognitive support at the encoding 
and retrieval phases of the episodic memory task. Manipulation of such support is of interest 
as earlier work (Bunce, 2001a, b) suggests the tasks most sensitive to underlying 
physiological mechanisms in older adults, are those placing the greatest demands on 
cognitive processes (i.e., low cognitive support). Here, we ask if vitamin B12 or folate, and 
APOE genotype interact to influence episodic memory in very old age, and whether 
cognitive support affects that relationship. 
APOE is involved in cholesterol transportation, and is determined by the combination 
of three alleles, ε2, ε3, and ε4. There is clear evidence that possession of the ε4 allele is a risk 
factor for dementia (for a review see Farrer, Cupples, Haines et al., 1997). However, work 
investigating whether the presence of the ε4 allele confers a greater vulnerability to cognitive 
impairment among non-demented older adults, is more equivocal. For example, individuals 
possessing the ε4 allele exhibited more precipitous decline in face and word recognition 
(Small, Basun, & Bäckman, 1998), delayed word recall (Hyman, Gomez-Isla, Briggs et al., 
1996), factor scores for episodic memory and processing speed (Hofer, Christensen, 
MacKinnon et al., 2002), memory and nonmemory composite measures (Jonker, Schmand, 
Lindeboom, Havekes, & Launer, 1998; Mayeux, Small, Tang, Tycko, & Stern, 2001), digit 
symbol and visuospatial skills (Mortensen & Hogh, 2001), and verbal and nonverbal 
reasoning (Deary, Whiteman, Pattie et al., 2002). By contrast, there is work suggesting no 
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association between the ε4 allele and decline in fluid intelligence (Pendleton, Payton, van 
den Boogard et al., 2002), composite visuospatial and language factors (Mayeux et al., 2001), 
and proxy measures of IQ (Deary, Whalley, St. Clair et al., 2003). Cross-sectional work 
found no association between APOE and episodic, semantic, or working memory, perceptual 
speed or visuospatial ability, after controlling for dementia (Bennett, Wilson, Schneider et 
al., 2003). Regarding measures of global cognitive performance, some studies suggest 
decline to be greater in ε4 carriers (e.g., Bretsky, Guralnik, Launer, Albert, & Seeman, 2003; 
Fillenbaum, Landerman, Blazer et al, 2001; Jonker et al., 1998), whereas others show no 
such differentials (Winnock, Letenneur, Jacqmin-Gadda et al., 2002). Given those equivocal 
findings, research that has investigated APOE in the presence of another deleterious 
physiological factor suggests that ε4 carriers are indeed more vulnerable to cognitive deficits. 
For instance, cognitive impairment was greater in ε4-carrying older adults suffering 
peripheral vascular disease, and atherosclerosis (Haan, Shemanski, Jagust, Manolio, & 
Kuller, 1999), olfactory dysfunction (Borenstein Graves, Bowen, Rajaram et al., 1999), and 
low estrogen use (Yaffe, Haan, Byers, Tangen, & Kuller, 2000). 
To date, little research has investigated nutritional factors and APOE ε4 in respect to 
cognitive performance in older adults. Earlier work suggests two B vitamins, B12 and folate, 
may provide a particularly worthwhile avenue for exploration. For instance, among older 
adults vitamin B12 and folate have been associated cross-sectionally with episodic memory 
(e.g., Hassing, Wahlin, Winblad, & Bäckman, 1999; Wahlin, Hill, Winblad, & Bäckman, 
1996), spatial, and working memory ability, and verbal fluency (Lindeman, Romero, Koehler 
et al., 2000; Robins Wahlin, Wahlin, Winblad, & Bäckman, 2001), and also with spatial 
copying skills (Riggs, Spiro, Tucker, & Rush, 1996). Intervention studies (e.g., Martin, 
Francis, Protetch et al., 1992; Meadows, Kaplan, & Bromfield, 1994) have established a link 
with improved cognition in demented or cognitively impaired individuals, and low levels of 
those nutrients have also been associated with an increased risk of developing Alzheimer’s 
disease (e.g., Wang, Wahlin, Basun et al., 2001). More broadly, there is evidence suggesting 
subclinical differences in those B vitamins may influence cognitive performance (see 
Calvaresi & Bryan, 2001).  
Together, those findings raise the possibility that possession of the ε4 allele and low 
B vitamin levels will increase vulnerability to cognitive impairment due to their combined 
deleterious effect on neural structures and processes. However, no empirical research has 
tested this possibility. Here, we address this shortfall in a population-based sample of 
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dementia- and depression-free adults aged 75 years and over. As noted earlier, there is 
evidence that demanding task conditions are more sensitive to underlying physiological 
mechanisms than those that are less demanding. Therefore, we manipulated the level of task 
demands by varying cognitive support at both the encoding and retrieval phases of an 
episodic free recall task. Finally, given the possibility that cerebro-, and cardiovascular 
diseases are related to both APOE, and vitamin B12 and folate levels, we took those 
influences into account in our investigation. 
 
     Method 
 
Participants 
The sample was drawn from inhabitants of the Kungsholmen parish in Stockholm, aged 75 
years or older, participating in a multidisciplinary project involving medical examination, 
social and family interviews, laboratory blood analysis, and cognitive testing (see Fratiglioni, 
Viitanen, Bäckman, Sandman, & Winblad, 1992, for a detailed description). Data were 
available for a total of 528 individuals. Of this number, 130 were diagnosed according to 
criteria in the Diagnostic and Statistical Manual of Mental Disorders III-R (American 
Psychiatric Association, 1987) as suffering dementia, and a further 33 depression. As 
inclusion of those individuals would affect interpretation of our results, they were removed 
from the statistical analyses. A further 37 were removed due to incomplete vitamin B12 or 
folate data, and also 16 participants who were taking vitamin B12 or folate supplements. 
Inspection of the remaining data revealed 32 individuals to have abnormally high folate 
levels. As such high values may be indicative of undetected disease, those persons also were 
removed from the sample. Finally, APOE data were unavailable for 113 persons. The final 
sample numbered 167, with a mean age of 82.81 years (SD = 5.68), was 80.24 percent 
female, and had a mean number of years education of 8.85 (SD = 2.98). A Table providing 
descriptive data for persons included in, and eliminated from, the sample can be viewed at 
[Hyperlink here]. For a minority of cases in the statistical analyses reported below, missing 
data were replaced by imputing the group mean for that variable. 
 
Episodic memory measures 
Free recall of semantically unrelated words. Two lists of 12 semantically unrelated concrete 
nouns were randomly selected from a pool of 48 nouns, equivalent in respect to visual and tactile 
imagery, meaningfulness, and frequency (Molander, 1984). The two lists were presented bimodally to 
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participants at either rapid (2 s per word) or slow (5 s per word) rates, counterbalanced across 
subjects. The interim interval was 1 s. Participants were told to remember as many words as possible 
for a subsequent recall test. Immediately following presentation, two minutes were allowed for oral 
free recall.  
Free and cued recall of organizable words. A further word list of 12 nouns belonging to four 
taxonomic categories was administered (i.e., clothes, furniture, professions, musical instruments) 
bimodally, at a rate of 5 s per word. Participants were not informed of the taxonomic categories 
beforehand. In free recall, participants were given two minutes to remember as many of the words as 
possible. A cued recall condition followed where the taxonomic categories served as cues. For each 
category, 30 s was allowed for recall. 
The episodic memory tasks can be conceived of as lying along a continuum of cognitive 
support. The lowest level of cognitive support was available in the condition allowing 2 s encoding 
time for semantically unrelated words. Cognitive support was increased in each condition, 
respectively, by extending encoding time for semantically unrelated words to 5 s, providing 
organizable taxonomic categories at encoding, and finally, offering cued recall of those taxonomic 
categories. 
 
Physiological variables 
 Cardio-, and cerebrovascular factors. As cardio-, and cerebrovascular factors may be 
independently associated with APOE, vitamin B12 and folate, and also cognitive performance 
in older adults, it was desirable to take those variables into account. Therefore, computerized 
hospital inpatient admission records were examined for the entire sample for the five-year 
period prior to cognitive testing. Admissions for any of the following complaints were 
recorded: diabetes, cerebrovascular diseases, stroke (hemorrhage, ischemic, or non-specific), 
transient ischemic attack, ischemic heart disease, heart failure, myocardial infarction, angina, 
arrhythmia, and arterial fibrillation. 
 Vitamin B12 and folate, and APOE.  Analyses of serum vitamin B12 and folate were 
conducted in the same laboratory using the radioimmunoassay method (see Chen, Silberstein, 
Maxon, Volle, & Sohnlein, 1982). APOE genotyping was conducted blind to clinical 
information, on DNA extracted from peripheral white blood cells. A microsequencing 
method involving polymerase chain reaction was used to determine the APOE genotype (see 
Small et al., 1998, for further details of this procedure).  
 
Procedure 
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The ethical committee of the Karolinska Institute, Stockholm, approved the project. 
A battery of cognitive measures, including the memory measures reported here, was 
administered. Blood samples for analyses of vitamin B12 and folate levels were collected on 
the morning of the day of cognitive testing.  
 Participants were classified as either APOE ε4 (ε2/ε4, ε3/ε4, ε4/ε4), or non- ε4 
(ε2/ε2, ε2/ε3, ε3/ε3). Within those groups, vitamin B12 and folate were stratified as follows: 
low B12 < 250 pmol/liter; low folate < 12 nmol/liter. Remaining participants, with values 
above those thresholds, were designated as normal. 
 
Results 
Vitamin B12, APOE and episodic memory 
Descriptive data relating to the four APOE-vitamin B12 groups for age, gender, years of 
education, and vitamin levels are presented in Table 1. Before the statistical analyses of 
primary interest were undertaken, several preliminary procedures were carried out. First, 
between-group differences in the biographical variables listed in Table 1 were subjected to a 
series of 2 x 2 ANOVAs where vitamin B12 (low/normal) and APOE genotype (ε4/non-ε4) 
formed between-subjects factors. For chronological age, the ANOVA revealed significant 
main effects for APOE, F(1,163) = 7.74, 
2
= .045, p = .006, and B12, F(1,163) = 19.22, 
2 
= 
.105, p<.001, but the APOE x B12 interaction was nonsignificant (p > .46). Members of the 
non-ε4 groups were older (83.61 versus 81.11 years), as were those in the low B12 groups 
(84.33 versus 80.39 years). Regarding years of education, the main effect for APOE, and the 
APOE x B12 interaction were statistically unreliable (ps>.71). However, persons with normal 
B12 levels had significantly more years of education (9.42 versus 8.21 years), F[1,163] = 
5.77, 
2
= .034, p = .017. Given those significant differences, both age and years of education 
were entered as covariates in the analyses reported below. Although a greater proportion of 
women made up the sample, gender was also entered as a covariate. 
 
    Table 1 about here 
 
 As noted earlier, it was desirable to take cardio- and cerebrovascular diseases into 
account. Initially, those variables were subjected to principal component analysis with 
varimax rotation for the following reasons. First, the procedure provides a means by which to 
reduce highly intercorrelated variables to meaningful clusters, thereby increasing reliability. 
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Also, it addresses the statistical problems associated with the use of dichotomous variables 
(i.e., participants either received a diagnosis for a disease, scored 1, or they did not, scored 
0), and for overlap of diagnoses in a particular episode (i.e., participants may receive several 
diagnoses in a specific episode of illness, underpinned by a common cause). Four factors 
resulted from this procedure, accounting for 78.09 percent of the explained variance. The 
diagnoses groupings related to stroke (hemorrhage, ischemic, and non-specific), coronary 
heart disease (ischemic, angina, myocardial infarction), other heart diseases (heart failure, 
arterial fibrillation, arrhythmia) and diabetes, and other cerebrovascular diseases (transient 
ischemic attack, cerebrovascular diseases). However, bivariate correlations did not suggest 
the factor scores arising from each of those four factors were correlated significantly with 
any of the cognitive variables. Neither did univariate analysis of variance (APOE and either 
B12 or folate formed the between-subjects factors) on each of those factors reveal any 
variation as a function of APOE, vitamin B12, or folate. Consideration of Table 1 suggests 
that the lack of association with cognitive, vitamin, or genetic variables may be due to the 
low prevalence of those diseases in this sample. Given that lack of association, 
cerebrovascular and cardiovascular diseases were not considered further in our analyses. 
 Turning to the main statistical analyses, episodic memory variables were subjected to 
a series of 2 x 2 x 2 Analyses of Covariance (ANCOVA), where B12 level (low/normal) and 
APOE genotype (ε4/non-ε4) formed the between-subject factors, and cognitive support the 
within-subjects factor (see below for specific details). In all analyses, age, years of education, 
and gender were entered as covariates. Descriptive data for episodic memory variables as a 
function of APOE and B12 group are also provided in Table 1. 
 
Free recall of semantically unrelated words following 2 s or 5 s encoding time 
The cognitive support within-subjects factor in this ANCOVA was the amount of time 
allowed for encoding, 2 s or 5 s. Statistics suggested recall performance of low B12-ε4 
carriers was below that of the other groups, but only in the faster, 2 s encoding condition; this 
group exhibited more marked improvement relative to other groups, when encoding time was 
increased to 5 s.  
 Specifically, while the main effect for APOE was not statistically reliable (p>.87), 
that for B12 was significant, F[1,160] = 16.86, 
2
 = .095, p =.001; Table 1 suggests persons 
with normal B12 levels recalled a greater number of words. The main effect for time support 
was also statistically reliable, F(1,163) = 4.17, 
2
 = .025, p = .043; greater time at encoding 
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was associated with superior recall. With the exception of that involving APOE and B12, 
(F[1,160] = 8.70, 
2
 = .052, p = .004), all two-way interactions were nonsignificant  (ps>.27). 
However, that significant two-way interaction was modified by a statistically reliable APOE 
x B12 x Time support interaction, F(1,163) = 5.72, 
2
=.034, p = .018. Consideration of Table 
1, suggests a relatively greater benefit was incurred in the ε4–low vitamin group from 2 s to 5 
s encoding conditions. Simple effects tests confirmed this impression. In the first tests, 
APOE group (ε4/non-ε4) was assessed within each level of vitamin group. That test for 
individuals of normal B12 levels was nonsignificant  (p>.48). The equivalent test within the 
low vitamin group however, reached significance, F(1,164) = 4.81, 
2
=.028, p =.030. Further 
simple effects tests were performed within the low vitamin group for both levels of APOE. 
That test for the non-ε4 group was not significant  (p>.95). Most importantly though, the test 
for the ε4 group reached significance, F(1,165) = 8.30, 
2
= .048, p =.005; the recall 
performance of ε4 carriers with low B12 levels significantly benefited when encoding time 
was increased from 2s to 5 s. 
 
Free recall of semantically unrelated versus organizational words 
The within-subjects factor in this ANCOVA was the degree of support intrinsic to the word 
lists at study; lists either were semantically unrelated (low support), or organizable into four 
taxonomic categories (higher support). Main effects were significant for vitamin group, 
F(1,160) = 6.66, 
2
= .040, p = .011, and the level of support available, F(1,163) = 38.06, 
2
= 
.189, p =.000; free recall means were higher for the normal B12 group, and for the word list 
with taxonomic categories embedded within it. The APOE main effect, and all interactions, 
were nonsignificant (ps>.38). In sum, increasing the level of support beyond provision of 5 s 
for encoding, resulted in parallel performance gains irrespective of APOE–vitamin group. 
 
Free versus cued recall of semantically organizable words       
In this ANCOVA, the level of cognitive support (the within-subjects factor) was manipulated 
through providing cued recall, relative to free recall, of taxonomic categories. The main 
effect for cognitive support was significant, F(1,163) = 261.33, 
2
= .616, p = .000; cued 
recall produced higher scores than free recall. However, all other statistics were 
nonsignificant (ps>.12). 
 In sum, the above analyses suggest the detrimental effect of ε4 in combination with 
low B12 levels was manifest in the most demanding condition of the present experiment (i.e., 
                                                                      ApoE, B vitamins, and episodic memory 10 
free recall following 2 s encoding time for semantically unrelated words). This can be seen in 
Table 1 by examining the third data column; the magnitude of the increase in recall 
performance from 2 s to 5 s encoding is greater in the ε4-low B12 group relative to the other 
groups. This between-group differential reduces as the level of cognitive support increases. 
 In considering the foregoing, it is important to take into account two factors that may 
have influenced our findings. First, dementia has a long preclinical phase, and it is possible 
that persons in our ε4-low B12 group were in the early stages of the disease. Data relating to 
incident dementia and mortality were available for participants three and six years following 
cognitive testing. In order to eliminate the possibility that our findings reflected the 
preclinical phase of the disease, all ANCOVAs were repeated, with incident dementia cases 
removed from the analyses. Regarding the second factor, investigators have used various cut-
offs to define low vitamin B12 levels. To confirm our results were not an artifact of the cut-
off we adopted, statistical analyses were also re-run but with low B12 status defined as <200 
pmol/liter. Analyses were repeated having removed incident dementia cases three and six 
years following testing. 
 
     Table 2 about here 
 
 The results of those additional analyses are summarized in Table 2. Significance 
levels for cut-offs <250 and <200 pmol/liter are presented to the left and right of the Table, 
respectively. Overall, the pattern of results from the re-analyses were remarkably consistent 
with those from the original, regardless of cut-off used to define low B12 status, or whether 
incident dementia cases were excluded from the analyses. Specifically, for analyses where 
low B12 was defined as <250 pmol/liter, when data three years following testing were taken 
into account, 20 demented, and 20 deceased participants were removed from the sample. An 
additional seven individuals declined participation at follow-up. The resulting sample 
numbered 120, were 79.17 percent female, had a mean age of 82.28 (SD = 5.08) years, and 
an average of 9.22 (SD = 3.29) years education. As age varied significantly according to B12 
group (p <.001), and years of education was marginal to conventional levels of statistical 
significance (p = .051), both variables, together with gender, were again entered as covariates 
into the analyses. 
 It can been seen in the third column of Table 2 that the results virtually replicated our 
earlier analyses. The ANCOVA comparing semantically unrelated words with 2 s versus 5 s 
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encoding time produced a significant main effect for cognitive support (p = .024), while main 
effects for APOE and B12 were both nonsignificant (ps>.15). As in the earlier analyses, 
greater time support was associated with superior aggregate recall performance. The APOE x 
B12 interaction was statistically reliable (p = .032), and the other two-way interactions were 
nonsignificant (p>.08). However, the APOE x B12 x Time Support interaction, again reached 
significance, this time with an increased effect size, F(1,116) = 6.77, 
2
= .055, p =.01. 
Inspection of group means and simple effects tests confirmed the source of the interaction to 
be the ε4/low B12 group in conditions of low cognitive support. Therefore, the removal of 
participants, who were either in the preclinical phase of dementia, deceased, or who refused 
participation three years following testing, did not affect our original results.  
 We then repeated those analyses having removed individuals diagnosed as demented 
six years following testing (see Table 2, Column 4). The consequent sample was 86. With 
this reduced sample (both low vitamin APOE groups numbered 12) the pattern of results was 
virtually the same, and the APOE x B12 x Time Support interaction attained significance, 
F(1,82) = 3.96, 
2
 = .046, p = .050. Although of reduced effect size, this again suggests our 
findings were uninfluenced by individuals in the preclinical phase of dementia during the six 
years following testing. We repeated this analysis on persons who were removed from the 
sample due to incident dementia in the six years following testing. T-tests revealed this group 
were significantly older (83.81 versus 81.91 years, p<.05), and had significantly fewer years’ 
education (8.10 versus 9.52, p<.01) than the nondemented group. In respect to APOE 
genotype, gender, B12 and folate levels, the two groups did not significantly differ. Notably 
though, the APOE x B12 x Time Support interaction became nonsignificant (p>.065) in the 
demented group suggesting further that our main finding was unrelated to the preclinical 
phase of dementia. Finally, ANCOVAs comparing free recall of unrelated words to those 
grouped into taxonomic categories, and free and cued recall of organizational words, with the 
exception of main effects for cognitive support (p < .001), found all other main effects and 
interactions were nonsignificant. This was the case when incident dementia cases three years, 
and also six years, following testing were removed from the sample. 
 Turning to statistical analyses where the B12 cut-off was lowered to <200 pmol/liter 
(as in the earlier analyses the normal group was defined as B12 >250 pmol/liter), the sample 
was reduced to 136 individuals. As statistically significant between-group differences existed 
in age, and years of education, those variables were again entered, with gender, as covariates 
into analyses. Table 2, Column 5 shows that the analyses, with one exception, replicated the 
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results obtained using the higher cut-off. The single statistic that differed was in the analysis 
of free recall following 2 s or 5 s encoding; the main effect for cognitive support that was 
significant in the original analysis, became nonsignificant. Removing participants either 
demented (n=11), deceased (n=16), or who declined further involvement in the study (n=7), 
three years later (consequent N = 102), rendered the main effects for B12 and time support 
nonsignificant for free recall following 2 s or 5 s encoding. All other statistics were as before. 
Although removal of individuals demented six years following testing reduced the sample 
considerably (n = 74; ε4-low B12 group = 8 individuals), again, the key interactions obtained 
in the original analyses, remained statistically reliable. Together, the reanalyses do not 
suggest that our findings were related to either the preclinical phase of dementia, or the cut-
off used to define low vitamin B12. 
 
Folate, APOE and episodic memory 
The foregoing statistical analyses were repeated, but with folate values determining the 
normal and low vitamin groups. Specifically, individuals with values <12 nmol/liter were 
designated as the low folate group, and those with values >12 as normal. Age, years of 
education, and gender were entered as covariates into the analyses. 
 For the ANCOVA comparing 2 s and 5 s encoding time, with the exception of a 
statistically significant main effect for cognitive support (F[1,163] = 6.79, 
2
 = .040, p = 
.010), none of the other main effects or interactions were statistically reliable (ps>.12). 
However, there was a nonsignificant trend in the data suggesting low folate-ε4 carriers to 
benefit from time support (2 s to 5 s) at encoding to a greater extent than other groups (see 
Table 3). We elected to explore this trend further through hierarchical multiple regression 
where the APOE x Folate cross-product interaction term was entered into the regression at 
the third step following age, education and gender (Step 1), and APOE and folate (Step 2). 
For 2 s encoding time for words, that interaction term added a 1.6 percent increment to the 
variance explained (p = .083), whereas for all other conditions that interaction was 
nonsignificant (ps>.21). Therefore, although unreliable at conventional levels of statistical 
significance, the trend in the data suggests that had the sample size and consequent statistical 
power been greater, the findings in respect to folate would have replicated those for vitamin 
B12. 
 Returning to the ANCOVAs comparing recall at higher levels of cognitive support, as 
was predominantly the case in analyses involving vitamin B12, only the cognitive support 
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main effect was statistically reliable (p<.001). All other main effects and interactions were 
nonsignificant. As in the earlier analyses, providing cognitive support improved free recall 
performance. As the ε4-low folate group numbered only 15 persons, removing those who 
were demented, deceased, or who refused participation three years or more following testing, 
rendered that cell too small for meaningful analyses. A similar problem was encountered 
when, following investigators elsewhere, a cut-off of <10 nmol/liter was adopted to define 
the low folate groups. Therefore, although the trend in the data was similar to that for vitamin 
B12, we are unable to draw any firm conclusions concerning low folate levels and APOE in 
respect to episodic memory in the present sample. 
 
     Table 3 about here 
 
     Discussion 
In this study, we have produced evidence that low B vitamin levels in combination with 
possession of the APOE ε4 allele is associated with an increased vulnerability to free recall 
deficits in old age. This association was found in respect to vitamin B12, but only in 
circumstances of high task demands, where cognitive support was low. Our findings are 
consistent with the vulnerability hypothesis, and are important for several reasons. First, they 
demonstrate the complexity of associations between genetic and non-genetic influences on 
episodic free recall in a population-based sample of older adults. Second, this is one of the 
first empirical demonstrations that nutritional factors interact multiplicatively with APOE 
genotype and the demands of a cognitive task to influence episodic memory in the very old; 
the benefits of providing cognitive support in demanding task conditions was greater in the 
ε4-low B12 group, relative to other groups. Third, the results qualify suggestions that 
associations between APOE genotype and cognitive performance are related to the 
preclinical phase of dementia. Our findings raise the possibility that there may be complex 
circumstances in which APOE exerts an influence on cognitive performance in older adults 
independently of future dementia. When individuals who became demented up to six years 
following testing were removed from the analyses, the findings were unaffected. 
Additionally, we took into account cerebro- and cardiovascular diseases, age, gender, and 
education. Furthermore, the results were not an artifact of the cut-offs used to define low B12 
levels, as they remained having lowered that cut-off. Those factors can therefore, be 
eliminated as potential confounds to our findings. 
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 As no previous research has assessed either vitamin B12, or folate, and APOE in 
respect to episodic memory, we elected to evaluate the two B vitamins separately. Although 
the variables are related, it is not yet known if any associations with APOE are mediated by 
the same, or differing, biochemical mechanisms. Our data suggested a dissociation, as a 
significant interaction was identified in relation to APOE and vitamin B12, but not folate. 
Before too much weight is attached to this finding though, consideration should be given to 
the following. First, in the statistical analyses involving ANCOVA, although the APOE x 
Folate x Cognitive support (2 s to 5 s) interaction was nonsignificant, the data trend was 
similar to that involving vitamin B12, suggesting the ε4-low folate group benefited more from 
additional time at encoding than the other groups. Second, after stratification according to 
APOE genotype, there were only 15 participants in the ε4-low folate group. Therefore, 
statistical power was limited in confirming differences where they existed. Additionally, as 
McClelland and Judd (1993) note, there are notorious difficulties associated with detecting 
statistically significant interactions in field studies such as this. Third, when hierarchical 
multiple regression was employed instead of ANCOVA, the amount of variance explained by 
the APOE x Folate cross-product interaction term approached conventional levels of 
statistical significance (p = .083). Finally, the small ε4-low folate group meant that we could 
not lower the threshold further to <10 nmol/liter as some researchers have done. Therefore, 
in the ANCOVAs it is possible that our low folate groups were not defined by sufficiently 
low values. Together, these considerations suggest that the differing findings for vitamin B12 
and folate were related to the small number of participants recording low folate values, rather 
than a dissociation in biochemical processes. 
 Given the foregoing, the findings build upon earlier work demonstrating the 
association between B vitamins, and cognitive performance in old age (e.g., Hassing et al., 
1996; Riggs et al., 1996; Wahlin et al., 1996). In the present study, the significant three-way 
interaction suggested the recall performance of low B12 ε4-carrying persons benefited more 
from increased cognitive support (2 s to 5 s encoding time). As recall conditions were 
identical (2 minutes) following both 2 s and 5 s encoding, it appears that the more limited 
study time deleteriously affected the encoding processes of ε4 carriers with low B12 vitamin 
levels. Bäckman (e.g., 1995) argues the benefits of cognitive support to older adults depend 
upon experimental factors (e.g., the type of support provided, and the cognitive ease with 
which it can be utilized), and individual differences (e.g., verbal ability). Also, recent work 
(Bunce, in press) indicates that cognitive support aids episodic memory performance in older 
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adults of lower, relative to higher, neuropsychological function. The present findings add to 
this work in two ways. First, in non-demented adults it appears that cognitive support also 
moderates biologically-based individual differences in respect to episodic memory. Second, 
when the statistical analyses were rerun only on persons who became demented up to six 
years following testing, the APOE x B12 x Cognitive support interaction became 
nonsignificant. Although on a smaller sample, this re-analysis suggests that the pathological 
progression of neurodegenerative diseases may reach a point at which cognitive support is no 
longer of benefit. Further work is required to explore such limitations in more detail. 
 Our findings have some important theoretical implications. Structural neuroimaging 
studies suggest that nondemented APOE ε4carriers have smaller hippocampi (Plassman, 
Welsh-Bohmer, Bigler et al., 1997), and suffer greater hippocampal atrophy (Cohen, Small, 
Lalonde, Friz, & Sunderland, 2001; Moffat, Szekely, Zonderman, Kabini, & Resnick, 2000). 
Moreover, there is work showing a greater magnitude and extent of brain activation among 
APOE ε4 carriers in the prefrontal cortex, hippocampus, and parietal cortex during a 
challenging memory task (Bookheimer, Strojwas, Cohen et al., 2000). It is suggested that 
such differences may represent compensatory recruitment of additional brain regions by 
APOE ε4 carriers while encoding into episodic memory in demanding conditions (Burggen, 
Small, Sabb, & Bookheimer, 2002). In addition, although the biological mechanisms by 
which B vitamins affect cognitive function are uncertain, two hypotheses have emerged 
(Calvaresi & Bryan, 2001). The hypomethylation hypothesis suggests low levels of B12 and 
folate interact to inhibit methylation throughout the central nervous system. Amongst other 
effects, this inhibits the metabolism of the neurotransmitters dopamine, norepinephrine, and 
serotonine, to the detriment of cognitive function. Alternatively, the homocysteine hypothesis 
proposes impaired neurocognitive function due to elevated levels of homocysteine arising 
from low vitamin B levels, and related cerebrovascular changes. From the present 
perspective, the notable feature is that both hypotheses suggest physiological mechanisms by 
which neurological processes either are impaired or damaged. Together, the deleterious 
influence of low B vitamin levels on neurological processes and structures in combination 
with the compromised neuroanatomical structures reported in ε4 carriers, may explain the 
free recall deficits we identified in ε4 carriers with low vitamin B12 levels. 
 Such an explanation is consistent with the vulnerability hypothesis, and it is also 
worth noting the link with the concept of brain reserve (e.g., Cummings, Vinters, Cole, & 
Khachaturian, 1998; Katzman, 1993; Mortimer, 1988; Satz, 1993; Skoog, 2002; Stern, 2002) 
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commonly used to explain the later onset of dementia among persons of higher education. 
Brain reserve is determined by the integrity of neuroanatomical structures and neural 
processes, and provides protection against the pathological progression of neurodegenerative 
disease in old age. In the present context, the neuroimaging work described earlier suggests 
that APOE ε4 carriers may have compromised or more vulnerable neuroanatomical reserves 
relative to non-ε4 carriers. Therefore, if an additional factor such as low B vitamin levels 
further depletes those reserves, the threshold at which cognitive deficits occur is more likely 
to be reached in ε4 carriers than non-ε4 carriers. Our data support this possibility, and 
highlight the value of future research investigating associations between APOE and cognitive 
performance in older adults while taking into account additional physiological factors that 
may influence that relationship. 
 Several investigators have argued that associations between the APOE ε4 allele and 
cognitive performance reflect the preclinical phase of dementia (e.g., Bondi, Salmon, 
Galasko, Thomas, & Thal, 1999; Small, Graves, McEvoy et al., 2000). Our findings 
however, suggest the picture may be more complex. Here, having removed incident dementia 
cases up to six years following testing, the findings remained statistically significant. It is 
possible therefore, that in certain complex circumstances, APOE exerts an influence on 
cognitive performance, independently of future dementia. The evidence here indicates the 
deleterious influence of an additional physiological factor, in combination with high 
cognitive demands, is one such circumstance. However, there is also empirical research 
showing APOE-related cognitive deficits disappear when future dementia is taken into 
account (Bondi et al., 1999). Given the lengthy preclinical phase of the disease, we cannot 
dismiss the possibility that the six-year period we took into account, was insufficiently long 
to identify all eventual dementia cases. Until further research is produced demonstrating 
APOE-related cognitive deficits having controlled for future dementia, our conclusions 
should be treated with caution. 
 The present study is not without its limitations. First, data relating to homocysteine 
levels were not available. Inclusion of such information would have helped demonstrate the 
extent to which low vitamin values were indicative of true deficiencies. Second, the 
advantages of a population-based study such as this, is that participant selection bias is 
limited. The downside though, is that analyses are restricted to the data available in that 
population. Here, the effects were twofold. After stratification by APOE and vitamin level, 
                                                                      ApoE, B vitamins, and episodic memory 17 
the group sizes were restricted, particularly in the case of folate. This not only limited 
statistical power, but also meant that we were unable to examine the ε4 dose effect.  
 Practically, the research suggests that a subsample of the non-demented elderly 
population (i.e., APOE ε4 carriers) may derive relatively greater benefits to cognitive 
performance from B12 and folate supplements, particularly when task demands are high. 
Recent research using transgenic mice (Kruman, Kumaravel, Lohani et al., 2002) has 
demonstrated depleted folate levels to be associated with the formation of the amyloid 
plaques found in Alzheimer’s disease, and work in humans also suggests a link between 
vitamin B12 and folate, and Alzheimer’s disease (Wang et al., 2001). Such findings, together 
with those of the present study, confirm there is good reason to consider inclusion of vitamin 
B12 and folate supplements as part of preventive health regimes for older persons. 
 The main conclusion of this study is that brain reserve may vary as a function of 
APOE genotype, and that ε4 carriers may be particularly vulnerable to cognitive impairment 
in the presence of an additional factor that deleteriously influences neuroanatomical 
structures and processes. The present study suggests vitamin B deficiencies to be one such 
factor. The findings appear unrelated to impending dementia up to six years following 
testing. It is clearly important that population-, and laboratory-based research further 
explores associations between APOE and cognitive performance in nondemented older adults 
while taking into account additional factors that may influence the vulnerability of 
neuroanatomical reserves. 
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Table 1. Biographical and memory variables as a function of apoE and vitamin B12  
 
 
 
 
 
                       Non-ε4                       ε4    
 
 
Low B12 Normal Low B12 Normal 
N 54 64 28 21 
     
Biographical 
 
Age 
 
 
 
85.91 (5.87) 
 
 
81.31 (5.32) 
 
 
82.75 (5.00) 
 
 
79.48 (2.98) 
% Women 75.93 79.69 92.86 76.19 
     
Education (yrs.) 8.38 (2.58) 9.41 (3.46) 8.04 (1.71) 9.43 (3.39) 
     
Diseases (n) 7 10 4 5 
     
Vitamin 
 
B12 (pmol/l) 
 
 
170.82 (57.27) 
 
 
381.59 (113.80) 
 
 
177.18 (53.81) 
 
 
386.38(126.02) 
     
  Folate 
(nmol/l) 
15.83 (5.89) 20.55 (9.90) 15.93 (7.94) 20.05 (10.02) 
 
Memory 
    
Unrelated 
 
2 s encoding 
 
 
 
4.78 (1.72) 
 
 
5.32 (1.62) 
 
 
3.68 (1.42) 
 
 
6.48 (2.18) 
5 s encoding 4.77 (1.90) 5.71 (1.64) 4.68 (2.13) 6.38 (2.56) 
     
  Organizable 
 
Free recall 
 
 
5.92 (2.24) 
 
 
6.91 (2.24) 
 
 
5.93 (2.36) 
 
 
7.14 (1.68) 
     
Cued recall 7.81 (2.32) 8.78 (2.10) 8.11 (2.67) 8.81 (1.66) 
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Table 2.  Significance levels for statistical analyses with B12 cut-offs at <250 or <200 
pmol/liter 
 
 
           Cut-off  <250  Cut-off <200  
2s Vs 5s Original 3yr rem 6yr rem Original 3yr rem 6yr rem 
 p= p= p= p= p= p= 
ApoE       
B12 .001   .004   
ApoE x B12 .004 .032 .004 .007 .025 .003 
CS .043 .024 .018   .044 
ApoE x CS      .042 
B12 x CS       
ApoE x B12 x CS .018 .010 .050 .045 .026 .042 
       
5s Vs Org       
ApoE       
B12 .011      
ApoE x B12       
CS .000 .000 .000 .000 .000 .000 
ApoE x CS       
B12 x CS       
ApoE x B12 x CS       
       
Org Vs Cued       
ApoE       
B12       
ApoE x B12       
CS .000 .000 .000 .000 .000 .000 
ApoE x CS       
B12 x CS       
ApoE x B12 x CS       
       
N1-6 167 120 86 136 102 74 
 
Notes.  Empty cell denotes statistic was nonsignificant 
 3 yr rem  = Demented up to 3 years post-test removed 
 6 yr rem  = Demented up to 6 years post-test removed 
 CS = Cognitive Support 
  2 s = 2 s encoding time for semantically unrelated words 
  5 s = 5 s encoding time for semantically unrelated words 
  Org = Free recall of semantically organizable words 
  Cued = Cued recall of semantically organizable words 
  N1-6 = Sample size for the respective analyses 
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Table 3. Biographical and memory variables as a function of apoE and folate 
 
 
 
                         Non-ε4                              ε4    
 
 
Low folate Normal Low folate Normal 
N 30 88 15 34 
     
Biographical 
 
Age 
 
 
 
84.97 (6.01) 
 
 
82.89 (5.96) 
 
 
81.33 (4.22) 
 
 
81.35 (4.71) 
% Women 70.00 80.68 93.33 82.35 
     
Education (yrs.) 9.67 (4.11) 8.69 (2.68) 8.00 (1.65) 8.91 (2.94) 
     
Diseases (n) 8 9 2 7 
     
Vitamin 
 
Folate (nmol/l) 
 
 
10.27 (1.44) 
 
 
21.16 (8.27) 
 
 
10.67 (1.18) 
 
 
20.79 (9.26) 
     
   B12 (pmol/l) 259.48 (142.90) 293.89 (138.64) 212.67 (105.26) 290.74 (145.90) 
 
Memory 
    
Unrelated 
 
2 s encoding 
 
 
 
4.68 (1.73) 
 
 
5.22 (1.65) 
 
 
4.27 (1.67) 
 
 
5.15 (2.44) 
5 s encoding 5.21 (2.04) 5.32 (1.74) 5.00 (2.24) 5.59 (2.55) 
     
  Organizable 
 
Free recall 
 
 
6.23 (2.19) 
 
 
6.55 (2.32) 
 
 
5.67 (2.09) 
 
 
6.79 (2.13) 
     
Cued recall 8.00 (2.07) 8.46 (2.30) 7.87 (1.92) 8.65 (2.07) 
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Hyperlink Table.  
 
Means and standard deviations for persons included in, and excluded from, the 
sample (Bunce, Kivipelto, & Wahlin) 
 
 
Variable Included Excluded Significance level 
    
Age 82.81 (5.68) 85.05 (5.05) <.01 
    
% women 80.24 80.90 ns 
    
Years 
education 
8.85 (2.98) 8.44 (2.28) ns 
    
No. diseases  26 (15.57%) 98 (27.15%) <.05 
    
B12 (pmol/l) 279.77 (139.35) 370 (342.38) <.01 
    
Folate (nmol/l) 18.19 (8.71) 23.17 (16.10) <.01 
    
N 167 361  
 
Notes. ns = nonsignificant 
The fourth column indicates if significant differences exist. Chi2 tests were 
used for women and diseases, and T-tests otherwise. 
